NEWS
![the panelists and host in video chat on a black background](/sites/default/files/styles/front_page_card/public/2022-06/COVID%20panel%20comp%20leaderboard.png?itok=qQk9BvIz)
Panel discussion spotlights COVID-19 R&D
The Data Science Institute's career panel series continued on June 28 with a discussion of LLNL’s COVID-19 research and development. Four data scientists talked about their work in drug screening, protein–drug compounds, antibody–antigen sequence analysis, and risk factor identification.
![image of cartoon people assembling puzzle pieces superimposed over a photo in which students and mentors stand as a group](/sites/default/files/styles/front_page_card/public/2022-07/uc-merced-dsc-comp-news.png?itok=fo1lbdgh)
UC Merced students work with LLNL mentors on potential new drugs to combat COVID-19
For the first time in the DSC series since the COVID-19 pandemic began in 2020, Lab mentors visited the college campus to provide in-person guidance for five teams of UC Merced students.
![two slides from Jim’s talk on a blue background alongside the ATOM logo and his portrait](/sites/default/files/styles/front_page_card/public/2022-06/ATOM-brase-comp-leaderboard.png?itok=lFzX3G6E)
Brase discusses advances by ATOM in accelerating drug discovery pipeline
The Accelerating Therapeutic Opportunities in Medicine (ATOM) consortium is showing “significant” progress in demonstrating that HPC and machine learning tools can speed up the drug discovery process, ATOM co-lead Jim Brase said at a recent webinar.